Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia
Identifieur interne : 003345 ( Main/Exploration ); précédent : 003344; suivant : 003346Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia
Auteurs : Stephan Klebe [Allemagne] ; Günther Deuschl [Allemagne] ; Henning Stolze [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adenosine Triphosphatases (genetics), Adult, Central Nervous System Stimulants (adverse effects), Central Nervous System Stimulants (therapeutic use), Chromosomes, Human, Pair 2, Female, Follow-Up Studies, Gait (drug effects), Hereditary spastic paraplegia, Human, Humans, Male, Methylphenidate, Methylphenidate (adverse effects), Methylphenidate (therapeutic use), Middle Aged, Muscle Tonus (drug effects), Nervous system diseases, Paraplegia (drug therapy), Signal Processing, Computer-Assisted, Spastic Paraplegia, Hereditary (drug therapy), Spasticity, Sporadic, Treatment Failure, gait analysis, hereditary spastic spinal paraplegia, methylphenidate, spasticity.
- MESH :
- chemical , adverse effects : Central Nervous System Stimulants, Methylphenidate.
- chemical , genetics : Adenosine Triphosphatases.
- chemical , therapeutic use : Central Nervous System Stimulants, Methylphenidate.
- drug effects : Gait, Muscle Tonus.
- drug therapy : Paraplegia, Spastic Paraplegia, Hereditary.
- Adult, Chromosomes, Human, Pair 2, Female, Follow-Up Studies, Humans, Male, Middle Aged, Signal Processing, Computer-Assisted, Treatment Failure.
Abstract
Based on its action on multiple neurotransmitters, including dopamine, methylphenidate (MPH) is of growing interest as a possible treatment option for several movement disorders. Of special interest are diseases that share gait disturbance and cognitive decline. Based on a single case observation in a patient with hereditary spastic spinal paraplegia (HSP) in which gait was improved with MPH, we performed an open‐label study with a longitudinal follow‐up in 22 patients with HSP and its sporadic form (SSP). The patients were treated for 6 months with 60 mg of MPH per day. Computerized gait analysis and different scores were performed at baseline, after 6 weeks, and after 6 months of treatment. Although at 6 weeks, the gait velocity was somewhat improved, the drug failed to show any effect on other gait parameters and had no beneficial effect at all after 6 months. Although MPH is of interest for several movement disorders, our study did not show a beneficial effect. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20973
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002B71
- to stream Istex, to step Curation: 002B71
- to stream Istex, to step Checkpoint: 001E04
- to stream PubMed, to step Corpus: 002C27
- to stream PubMed, to step Curation: 002C27
- to stream PubMed, to step Checkpoint: 002C37
- to stream Ncbi, to step Merge: 001707
- to stream Ncbi, to step Curation: 001707
- to stream Ncbi, to step Checkpoint: 001707
- to stream Main, to step Merge: 004658
- to stream PascalFrancis, to step Corpus: 001991
- to stream PascalFrancis, to step Curation: 001330
- to stream PascalFrancis, to step Checkpoint: 001A21
- to stream Main, to step Merge: 004B16
- to stream Main, to step Curation: 003345
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia</title><author><name sortKey="Klebe, Stephan" sort="Klebe, Stephan" uniqKey="Klebe S" first="Stephan" last="Klebe">Stephan Klebe</name></author><author><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name></author><author><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A0F1CAF24C7EDF3DB0F29EB9D427FABD0B399A94</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20973</idno><idno type="url">https://api.istex.fr/document/A0F1CAF24C7EDF3DB0F29EB9D427FABD0B399A94/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002B71</idno><idno type="wicri:Area/Istex/Curation">002B71</idno><idno type="wicri:Area/Istex/Checkpoint">001E04</idno><idno type="wicri:doubleKey">0885-3185:2006:Klebe S:methylphenidate:fails:to</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16705687</idno><idno type="wicri:Area/PubMed/Corpus">002C27</idno><idno type="wicri:Area/PubMed/Curation">002C27</idno><idno type="wicri:Area/PubMed/Checkpoint">002C37</idno><idno type="wicri:Area/Ncbi/Merge">001707</idno><idno type="wicri:Area/Ncbi/Curation">001707</idno><idno type="wicri:Area/Ncbi/Checkpoint">001707</idno><idno type="wicri:doubleKey">0885-3185:2006:Klebe S:methylphenidate:fails:to</idno><idno type="wicri:Area/Main/Merge">004658</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0518105</idno><idno type="wicri:Area/PascalFrancis/Corpus">001991</idno><idno type="wicri:Area/PascalFrancis/Curation">001330</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001A21</idno><idno type="wicri:doubleKey">0885-3185:2006:Klebe S:methylphenidate:fails:to</idno><idno type="wicri:Area/Main/Merge">004B16</idno><idno type="wicri:Area/Main/Curation">003345</idno><idno type="wicri:Area/Main/Exploration">003345</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia</title><author><name sortKey="Klebe, Stephan" sort="Klebe, Stephan" uniqKey="Klebe S" first="Stephan" last="Klebe">Stephan Klebe</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Christian‐Albrechts‐Universität zu Kiel, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author><author><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Christian‐Albrechts‐Universität zu Kiel, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author><author><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Christian‐Albrechts‐Universität zu Kiel, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-09">2006-09</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1468">1468</biblScope><biblScope unit="page" to="1471">1471</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A0F1CAF24C7EDF3DB0F29EB9D427FABD0B399A94</idno><idno type="DOI">10.1002/mds.20973</idno><idno type="ArticleID">MDS20973</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Triphosphatases (genetics)</term><term>Adult</term><term>Central Nervous System Stimulants (adverse effects)</term><term>Central Nervous System Stimulants (therapeutic use)</term><term>Chromosomes, Human, Pair 2</term><term>Female</term><term>Follow-Up Studies</term><term>Gait (drug effects)</term><term>Hereditary spastic paraplegia</term><term>Human</term><term>Humans</term><term>Male</term><term>Methylphenidate</term><term>Methylphenidate (adverse effects)</term><term>Methylphenidate (therapeutic use)</term><term>Middle Aged</term><term>Muscle Tonus (drug effects)</term><term>Nervous system diseases</term><term>Paraplegia (drug therapy)</term><term>Signal Processing, Computer-Assisted</term><term>Spastic Paraplegia, Hereditary (drug therapy)</term><term>Spasticity</term><term>Sporadic</term><term>Treatment Failure</term><term>gait analysis</term><term>hereditary spastic spinal paraplegia</term><term>methylphenidate</term><term>spasticity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Central Nervous System Stimulants</term><term>Methylphenidate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Adenosine Triphosphatases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Central Nervous System Stimulants</term><term>Methylphenidate</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gait</term><term>Muscle Tonus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Paraplegia</term><term>Spastic Paraplegia, Hereditary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Chromosomes, Human, Pair 2</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Signal Processing, Computer-Assisted</term><term>Treatment Failure</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Homme</term><term>Hypertonie spastique</term><term>Méthylphénidate</term><term>Paraplégie spasmodique héréditaire Strumpell Lorrain</term><term>Sporadique</term><term>Système nerveux pathologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Based on its action on multiple neurotransmitters, including dopamine, methylphenidate (MPH) is of growing interest as a possible treatment option for several movement disorders. Of special interest are diseases that share gait disturbance and cognitive decline. Based on a single case observation in a patient with hereditary spastic spinal paraplegia (HSP) in which gait was improved with MPH, we performed an open‐label study with a longitudinal follow‐up in 22 patients with HSP and its sporadic form (SSP). The patients were treated for 6 months with 60 mg of MPH per day. Computerized gait analysis and different scores were performed at baseline, after 6 weeks, and after 6 months of treatment. Although at 6 weeks, the gait velocity was somewhat improved, the drug failed to show any effect on other gait parameters and had no beneficial effect at all after 6 months. Although MPH is of interest for several movement disorders, our study did not show a beneficial effect. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Schleswig-Holstein</li></region><settlement><li>Kiel</li></settlement></list><tree><country name="Allemagne"><region name="Schleswig-Holstein"><name sortKey="Klebe, Stephan" sort="Klebe, Stephan" uniqKey="Klebe S" first="Stephan" last="Klebe">Stephan Klebe</name></region><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name><name sortKey="Stolze, Henning" sort="Stolze, Henning" uniqKey="Stolze H" first="Henning" last="Stolze">Henning Stolze</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003345 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003345 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A0F1CAF24C7EDF3DB0F29EB9D427FABD0B399A94
|texte= Methylphenidate fails to improve gait and muscle tone in patients with sporadic and hereditary spastic paraplegia
}}
| This area was generated with Dilib version V0.6.23. |  |